Deutsche Bank AG increased its stake in shares of PerkinElmer, Inc. (NYSE:PKI) by 59.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 177,244 shares of the medical research company’s stock after buying an additional 65,985 shares during the quarter. Deutsche Bank AG’s holdings in PerkinElmer were worth $13,919,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc grew its holdings in shares of PerkinElmer by 1.7% during the third quarter. Vanguard Group Inc now owns 11,628,380 shares of the medical research company’s stock valued at $1,131,092,000 after buying an additional 198,673 shares during the last quarter. BlackRock Inc. grew its holdings in shares of PerkinElmer by 7.4% during the fourth quarter. BlackRock Inc. now owns 7,001,732 shares of the medical research company’s stock valued at $549,985,000 after buying an additional 482,906 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of PerkinElmer by 10.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,766,757 shares of the medical research company’s stock valued at $295,879,000 after buying an additional 353,534 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of PerkinElmer by 8.9% during the fourth quarter. Geode Capital Management LLC now owns 1,522,499 shares of the medical research company’s stock valued at $119,450,000 after buying an additional 124,168 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in shares of PerkinElmer by 0.9% during the fourth quarter. Northern Trust Corp now owns 1,068,924 shares of the medical research company’s stock valued at $83,965,000 after buying an additional 9,454 shares during the last quarter. 96.39% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts have recently weighed in on PKI shares. CIBC reissued an “average” rating and set a $44.50 price objective on shares of PerkinElmer in a report on Thursday, January 10th. Morgan Stanley dropped their price objective on shares of PerkinElmer from $100.00 to $86.00 and set an “overweight” rating on the stock in a report on Thursday, January 3rd. UBS Group set a $92.00 price objective on shares of PerkinElmer and gave the company a “hold” rating in a report on Saturday, February 2nd. Needham & Company LLC started coverage on shares of PerkinElmer in a research report on Wednesday, January 2nd. They set a “hold” rating and a $79.00 target price for the company. Finally, Cowen restated a “hold” rating and set a $85.00 target price on shares of PerkinElmer in a research report on Sunday, January 6th. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $85.06.
NYSE PKI opened at $99.99 on Monday. The firm has a market cap of $11.13 billion, a P/E ratio of 27.70, a price-to-earnings-growth ratio of 2.19 and a beta of 1.25. PerkinElmer, Inc. has a 1 year low of $70.83 and a 1 year high of $103.00. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.60 and a quick ratio of 1.16.
PerkinElmer (NYSE:PKI) last posted its earnings results on Thursday, January 31st. The medical research company reported $1.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.16 by $0.02. The company had revenue of $756.35 million during the quarter, compared to the consensus estimate of $746.15 million. PerkinElmer had a net margin of 8.56% and a return on equity of 15.89%. During the same period in the previous year, the firm posted $0.97 earnings per share. On average, equities analysts predict that PerkinElmer, Inc. will post 4.03 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Friday, April 19th will be given a dividend of $0.07 per share. The ex-dividend date is Wednesday, April 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.28%. PerkinElmer’s dividend payout ratio is presently 7.76%.
PerkinElmer Company Profile
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil.
Featured Story: How does inflation affect different investments?
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.